The deregistration is the final step in the going-private transaction. No further public trading or SEC filings are expected. Shareholders who tendered shares in the merger have already received the $3.16 per share plus CVR consideration. Monitor for any post-merger CVR events or appraisal rights deadlines.
ESPR drugs
ESPR drug pipeline →Price Chart
Executive Summary
Esperion Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g), effective immediately. This is the final procedural step following the company's delisting from Nasdaq on July 13, 2026, after its acquisition by ArchiMed (via Essence Parent Inc.). With only 1 holder of record, the company will cease all SEC reporting obligations, completing its transition to a private entity.
Key Facts
- Form 15-12G filed to terminate registration under Section 12(g) of the Securities Exchange Act of 1934.
- Approximate number of holders of record as of the certification date: 1.
- Filing follows a 25-NSE delisting from Nasdaq on July 13, 2026, related to the acquisition by ArchiMed.
- The company will no longer file periodic reports with the SEC (Forms 10-K, 10-Q, 8-K, etc.).
Financial Impact
No financial figures provided in the filing. The deregistration is a procedural step after the completed acquisition; the company is now private.
Risk Factors
- No ongoing public disclosure or SEC oversight for the company.
- Minority shareholders who did not tender may face illiquidity and limited information rights.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (Primary) | 0001104659-26-086097 |
| Document: 0001104659-26-086097-index-headers.html | 0001104659-26-086097 |
| Document: 0001104659-26-086097-index.html | 0001104659-26-086097 |
| Document: 0001104659-26-086097.txt | 0001104659-26-086097 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 Viewing No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers